228 recessive genetic disorders identified by Hiro Clinic

What You Will Learn on This Page

  • What a “carrier” is and why approximately 70% of people fall into this category
  • Why “couple testing,” where both partners are tested together, is important
  • Up to 231 recessive genetic disorders identified by Carrier Screening Test 231
  • Testing process, optional fees, and turnaround time for results
  • Steps you can take if risks are detected (such as amniocentesis support)

70% of Parents Are Carriers? The Utility of Recessive Gene Testing

70% of people carry some form of genetic anomaly (mutation).
Individuals with such genetic mutations are called “carriers.”
Even if there are no visible or physical abnormalities, that gene can potentially affect their children.
When both parents carry a mutation in the same gene, the probability of their child developing the disease is 25%, the probability of becoming a carrier is 50%, and the probability of inheriting normal genes is 25%.

Testing Recommended Worldwide Testing Recommended Worldwide

So, what kind of testing is performed for these individuals? Also, what types of diseases can be identified?

What is a “Carrier”? Normal Gene Mutated Gene If one gene is normal, symptoms will not develop = An asymptomatic “Carrier” state In Japan, approximately 70% of people are said to be carriers of some kind When both partners carry the same mutation, their child will be… Affected 25% Carrier 25% Carrier 25% Unaffected 25% Ratio: 25% Affected / 50% Carrier / 25% Unaffected That is why taking “Couple Testing” together as a couple is essential
How Being a Carrier Works and the Importance of Couple Testing

① What is Carrier Screening Test 231 at Hiro Clinic?

Hiro Clinic offers a prenatal screening test that can examine genes associated with up to 231 severe recessive genetic disorders affecting the fetus. This screening is internationally recognized as crucial, with major medical organizations such as the American College of Obstetricians and Gynecologists (ACOG) and the American Society of Human Genetics (ASHG) recommending that information about it be widely provided.
Recessive genetic disorders are conditions that can develop in a child when both the father and mother carry mutations in the same gene. In this test, genetic material is collected from the oral mucosa (inner cheek) of both the father and mother to check whether both parents carry the same mutation.

Photo of testing kit

According to research by Hiro Clinic, approximately 70% of individuals are found to carry one or more recessive gene mutations. This state is known as being a “carrier” (gene carrier)—a condition where, despite having no visible symptoms or physical health issues, there is a possibility of passing the gene on to their children.

When both parents carry the same genetic mutation, the risk of their child developing the disease follows these probabilities:

  • 25% chance (1 in 4) of developing the disease
  • 50% chance (1 in 2) of becoming an asymptomatic carrier
  • 25% chance (1 in 4) of inheriting normal genes
When both parents carry the same genetic mutation

If high risk is identified through this test, amniocentesis may be recommended as a confirmatory test.

② Gene “Mutations” Can Sometimes Cause Disease

Our bodies are built according to genetic information that functions like a blueprint. Humans have approximately 20,000 genes, which are passed down from parents to their children. They contain essential information that determines various characteristics, such as hair color, height, and physical constitution.
However, in rare cases, mutations occur in this blueprint. These mutations can sometimes lead to specific diseases.
For example, diseases caused by a mechanism called “recessive inheritance” develop only when a child receives the same type of gene mutation from both the father and the mother. Even if only one parent carries the mutation, the individual will not develop the recessive genetic disorder.
One example of a recessive genetic disorder involves a mutation in the OCA2 gene located on chromosome 15. If a child inherits two copies of this mutation—one from the father and one from the mother—the body becomes unable to produce the “P protein,” which is essential for synthesizing “melanin,” the pigment that determines the color of skin, hair, and eyes. Consequently, melanin is not produced, resulting in a condition known as “Oculocutaneous Albinism,” where the skin and hair appear white.

Diagram explaining how inheriting the same genetic mutation from both parents leads to disease onset through recessive inheritance

In addition, diseases caused by abnormalities in the “X chromosome”—a sex chromosome—are known as X-linked recessive disorders, which characteristically affect males more frequently. Because males have only one X chromosome, if a mutation is present, there is no alternative copy to compensate for it, making disease manifestation more likely. On the other hand, females have two X chromosomes; even if one carries an abnormality, as long as the other functions normally, it can compensate for the defect, making disease development far less common.

③ Inherited Disorders That Can Happen to Anyone

Recessive genetic diseases are often thought to be rare, but in fact, there are more than 3,000 distinct types. Taken together, it is estimated that 1 to 2 out of every 100 couples may have a child born with a genetic disorder. In other words, this is a topic that concerns everyone.
For this reason, undergoing screening prior to or during early pregnancy allows couples to calmly consider their options even if a risk is detected. Options may include selecting healthy embryos through in vitro fertilization (IVF) or confirming the baby’s condition after pregnancy via amniocentesis.

④ Also Helpful for Managing Mother and Child Health

Carrier Screening Test 231 not only provides insight into a child’s disease risks but also aids in managing the mother’s health. For example, if risks such as a tendency to bleed—which requires caution during pregnancy—or cardiac disease risks can be identified in advance, doctors can prepare accordingly ahead of time.

Diagram showing how Carrier Screening Test 231 is also helpful for maternal health management
Diagram illustrating what can be identified through Carrier Screening Test 231

In this way, Carrier Screening Test 231 serves as valuable support for a reassuring pregnancy and childbirth. At Hiro Clinic, this screening can be combined with NIPT (Non-Invasive Prenatal Testing). For patients undergoing NIPT, Carrier Screening Test 231 is offered at an optional discounted rate. Naturally, individuals who do not undergo NIPT can also take this test as a standalone option.

⑤ Japanese-Specific Genetic Risks

In Japan, there was a historical period when marriages between cousins were common, which made it easier for specific gene mutations to persist within the population. Consequently, certain genetic conditions are more prevalent among Japanese people.
For example, it has become clear that among eye-related genetic disorders, conditions such as “retinitis pigmentosa” and “fundus albipunctatus” are particularly frequent in Japan. In particular, the EYS gene has been identified as the most frequent causative gene for retinitis pigmentosa in Japanese individuals. Because these diseases are often caused by specific gene mutations, they are surprisingly relevant and close to home.

Diagram showing hereditary eye diseases common in Japan, such as retinitis pigmentosa

Such genetic mutations specific to the Japanese population are sometimes not included in overseas databases. Therefore, Carrier Screening Test 231, which is tailored specifically for Japanese individuals, is extraordinarily important.

⑥ Toward Future Healthcare: A Fair Society Where Everyone Has Choices

Future healthcare will focus on “preventing disease” rather than simply “treating disease after it occurs.” Carrier Screening Test 231 represents a vital first step in this direction.
In countries like Australia and the Netherlands, initiatives are underway to incorporate recessive gene testing into national healthcare systems. In Japan, too, there is a growing need to establish systems that allow insurance coverage so that all couples can access screening fairly.
At Hiro Clinic, we recommend Carrier Screening Test 231 for couples, including as part of a pre-marital bridal checkup before pregnancy. Undergoing testing early provides essential decision-making information for future family planning, pregnancy, and childbirth. It allows couples to share results and calmly prepare for delivery.
Furthermore, performing Carrier Screening Test 231 on newborn infants enables early detection of future health risks, facilitating personalized healthcare management. The test can be performed painlessly simply by collecting a sample with a gentle cheek swab.
This screening represents a choice to “know,” aiming to protect future lives. Making this test—which is recommended by major medical societies in the United States—widely understood and accessible to many in Japan is what modern healthcare strives to achieve.

参考・引用文献

  • Li, Huanyun, et al. ‘P806: Application Value of Noninvasive Prenatal Diagnosis of Recessive Monogenic Genetic Diseases Based on Relative Haplotype Dosage Changes’. Genetics in Medicine Open, vol. 3, 2025, p. 103175. DOI.org (Crossref), https://doi.org/10.1016/j.gimo.2025.103175.
  • Temaj, G., et al. ‘The Impact of Consanguinity on Human Health and Disease with an Emphasis on Rare Diseases’. Journal of Rare Diseases, vol. 1, no. 1, Dec. 2022, p. 2. DOI.org (Crossref), https://doi.org/10.1007/s44162-022-00004-5.
  • Peterlin, Borut, and Ana Peterlin. ‘Carrier Screening and Pregnancy’. Best Practice & Research Clinical Obstetrics & Gynaecology, vol. 100, June 2025, p. 102601. DOI.org (Crossref), https://doi.org/10.1016/j.bpobgyn.2025.102601.
  • Hotta, Yoshihiro, et al. ‘Ocular Genetics in the Japanese Population’. Japanese Journal of Ophthalmology, vol. 68, no. 5, Sept. 2024, pp. 401–18. DOI.org (Crossref), https://doi.org/10.1007/s10384-024-01109-8.
  • Wang, Tianjiao, et al. ‘An Overview of Reproductive Carrier Screening Panels for Autosomal Recessive and/or X‐linked Conditions: How Much Do We Know?’ Prenatal Diagnosis, vol. 43, no. 11, Oct. 2023, pp. 1416–24. DOI.org (Crossref), https://doi.org/10.1002/pd.6434.
  • Dive, Lisa, et al. ‘Ethical Considerations in Gene Selection for Reproductive Carrier Screening’. Human Genetics, vol. 141, no. 5, May 2022, pp. 1003–12. DOI.org (Crossref), https://doi.org/10.1007/s00439-021-02341-9.
  • Edwards, Samantha, and Nigel Laing. ‘Genetic Counselling Needs for Reproductive Genetic Carrier Screening: A Scoping Review’. Journal of Personalized Medicine, vol. 12, no. 10, Oct. 2022, p. 1699. DOI.org (Crossref), https://doi.org/10.3390/jpm12101699.
  • Prabhu, Akshatha. ‘Fetal Medicine and Current Practice of Prenatal Screening’. Apollo Medicine, vol. 20, no. 2, June 2023, pp. 135–38. DOI.org (Crossref), https://doi.org/10.4103/am.am_60_23.
  • Veneruso, Iolanda, et al. ‘Current Updates on Expanded Carrier Screening: New Insights in the Omics Era’. Medicina, vol. 58, no. 3, Mar. 2022, p. 455. DOI.org (Crossref), https://doi.org/10.3390/medicina58030455.
  • Srinivasan, Balaji S., et al. ‘A Universal Carrier Test for the Long Tail of Mendelian Disease’. Reproductive BioMedicine Online, vol. 21, no. 4, Oct. 2010, pp. 537–51. DOI.org (Crossref), https://doi.org/10.1016/j.rbmo.2010.05.012.
  • Nguengang Wakap, Stéphanie, et al. ‘Estimating Cumulative Point Prevalence of Rare Diseases: Analysis of the Orphanet Database’. European Journal of Human Genetics, vol. 28, no. 2, Feb. 2020, pp. 165–73. www.nature.com, https://doi.org/10.1038/s41431-019-0508-0.
  • Chung, Brian Hon Yin, et al. ‘Rare versus Common Diseases: A False Dichotomy in Precision Medicine’. Npj Genomic Medicine, vol. 6, no. 1, Feb. 2021, p. 19. DOI.org (Crossref), https://doi.org/10.1038/s41525-021-00176-x.
  • Faye, Fatoumata, et al. ‘Time to Diagnosis and Determinants of Diagnostic Delays of People Living with a Rare Disease: Results of a Rare Barometer Retrospective Patient Survey’. European Journal of Human Genetics, vol. 32, no. 9, Sept. 2024, pp. 1116–26. DOI.org (Crossref), https://doi.org/10.1038/s41431-024-01604-z.
  • Laing, Nigel G., et al. ‘Genetic Neuromuscular Disorders: What Is the Best That We Can Do?’ Neuromuscular Disorders, vol. 31, no. 10, Oct. 2021, pp. 1081–89. DOI.org (Crossref), https://doi.org/10.1016/j.nmd.2021.07.007.
  • https://www.info.pmda.go.jp/downfiles/md/PDF/200880/200880_28B3X10006000050_A_01_01.pdf

Testing Process

Carrier Screening Test 231 is completed in 3 simple steps: applying at the clinic, collecting a buccal (inner cheek) swab, and receiving email results approximately 3 weeks later.

Step 1

Apply for the Test at the Clinic

At the time of application, consent forms must be filled out by both the expectant mother and her partner.
The testing kit will be provided during your visit.
※Both the pregnant mother and her partner must visit the clinic together.
Step 2
Rub the shaft of the testing swab against the inner cheek mucosa (inside the mouth) to collect cells.
※Please refrain from smoking, eating, drinking, brushing teeth, or chewing gum within 30 minutes prior to collection.
Hand in the collected sample at the clinic before leaving.
Step 3

Test Results Notification

Results will be delivered via email approximately 3 weeks later.
※This report is separate from the results of the maternal blood test.
※The test results will be ready approximately 3 weeks after the sample arrives at the laboratory.

Optional Pricing for
Carrier Screening Test 231

When ordered together with NIPT, Carrier Screening Test 231 is available at a discounted optional price. Standalone testing is also available.

Testing for Up to 231 Recessive Genetic Disorders PC View
Testing for 228 Recessive Genetic Disorders Mobile View

How Recessive Genetic Disorders Develop

Humans have two copies of each chromosome: one inherited from the mother and one from the father.

A recessive genetic disorder occurs when there is a mutation in the genes located at the same position on both of these chromosomes. If only one chromosome—either from the mother or the father—has a mutation, but the corresponding gene on the other chromosome is normal, the disorder will not develop. As long as one copy is normal, the individual will not become ill, and that person is referred to as a “carrier.”

The risk increases when biological relatives have children together because the likelihood of sharing the same carrier status is higher among relatives. For example, in a rare condition that affects 1 in 40,000 individuals, the carrier rate is estimated to be approximately 1 in 100. This is based on the calculation: 1/100 × 1/100 × 1/4 = 1/40,000. Therefore, if you test for 100 different conditions, it is likely that almost everyone is a carrier of at least one condition.

So, what happens if our clinic’s test detects a mutation at the exact same gene location in both parents?

If both parents happen to carry a mutation in the same gene, their child is at risk for developing a recessive genetic disorder. This is because there is no normal copy at that gene location, making disease onset possible.

  • 1 in 4 fetuses (25%) will be affected.
  • 1 in 2 fetuses (50%) will be carriers.
  • 1 in 4 fetuses (25%) will be unaffected.

How can we check if the baby has inherited these mutations?

One of the most accurate methods to detect genetic abnormalities is amniocentesis. In this test, genetic analysis is performed using fetal cells obtained from the amniotic fluid.

By enrolling in our Amniocentesis Support program, you can receive up to ¥300,000 (tax included) in subsidies depending on your plan. In many cases, this covers the entire cost of the amniocentesis, allowing you to undergo the test at no out-of-pocket expense.
If you wish to undergo testing, please contact Hiro Clinic.

Recessive Genetic Disorders Identified by Hiro Clinic NIPT

Carrier Screening Test 231 examines causative genes for up to 231 types of recessive genetic disorders. You can also view detailed pages by clicking on the disease name of interest.

Disease Name (JP) Disease Name (EN) Genes Tested at Our Clinic Chromosome Location Detailed Information
3-ヒドロキシ-3-メチルグルタル酸血症 3-Hydroxy-3-Methylglutaryl-Coenzyme A Lyase Deficiency HMGCL 1p36.1 Click here for details on this condition
ライディッヒ細胞形成不全(黄体形成ホルモン抵抗性) Leydig Cell Hypoplasia [Luteinizing Hormone Resistance] LHCGR 2p16.3 Click here for details on this condition
3-メチルクロトニルCoAカルボキシラーゼ欠損症 3-Methylcrotonyl-CoA Carboxylase Deficiency 1 MCCC1 3q27.1 Click here for details on this condition
肢帯型筋ジストロフィーⅡE型 Limb Girdle Muscular Dystrophy, Type 2E SGCB 4q12 Click here for details on this condition
複合カルボキシラーゼ欠損症 3-Methylcrotonyl-CoA Carboxylase Deficiency 2 MCCC2 5q13.2 Click here for details on this condition
ジヒドロリポアミドデヒドロゲナーゼ欠損症(メープルシロップ尿症III型) Lipoamide Dehydrogenase Deficiency [Maple Syrup Urine Disease, Type 3] DLD 7q31.1 Click here for details on this condition
無βリポ蛋白血症 Abetalipoproteinemia MTTP 4q23 Click here for details on this condition
リポタンパク質リパーゼ欠損症 Lipoprotein Lipase Deficiency LPL 8p21.3 Click here for details on this condition
アシルCoAオキシダーゼI欠損症 Acyl-CoA Oxidase I Deficiency ACOX1 17q25.1 Click here for details on this condition
オーメン症候群(RAG2関連) Omenn Syndrome (RAG2-related) RAG2 11p12 Click here for details on this condition
神経有棘赤血球症 Chorea-acanthocytosis VPS13A 9q21.2 Click here for details on this condition
オルニチンアミノトランスフェラーゼ欠損症 Ornithine Aminotransferase Deficiency OAT 10q26.13 Click here for details on this condition
X連鎖性脈絡膜血症 Choroideremia, X-Linked CHM Xq21.2 Click here for details on this condition
高オルニチン血症-高アンモニア血症-ホモシトルリン血症(HHH)症候群 Ornithine Translocase Deficiency Hyperornithinemia-Hyperammonemia -Homocitrullinuria (HHH) Syndrome] SLC25A15 13q14.11 Click here for details on this condition
シトリン欠損症 Citrin Deficiency SLC25A13 7q21.3 Click here for details on this condition
ペンドレッド症候群 Pendred Syndrome SLC26A4 7q22.3 Click here for details on this condition
複合酸化的リン酸化欠損症3 Combined Oxidative Phosphorylation Deficiency 3 TSFM 12q14.1 Click here for details on this condition
ゼルウェーガースペクトル症候群(PEX1) Peroxisome Biogenesis Disorders Zellweger Syndrome Spectrum (PEX1-related) PEX1 Click here for details on this condition
先天性グリコシル化異常症Ⅰ型(PMM2関連) Congenital Disorder of Glycosylation, Type 1A (PMM2-related) PMM2 16p13.2 Click here for details on this condition
ゼルウェーガースペクトル症候群(PEX2) Peroxisome Biogenesis Disorders Zellweger Syndrome Spectrum (PEX2-related) PEX2 Click here for details on this condition
遺伝性フルクトース不耐症 Hereditary Fructose Intolerance ALDOB 9q31.1 Click here for details on this condition
ツェルウェガー症候群 Peroxisome Biogenesis Disorders Zellweger Syndrome Spectrum (PEX1-related) PEX1 7q21.2 Click here for details on this condition
ホモシスチン尿症cblE型 Homocystinuria, Type cblE MTRR 5p15.31 Click here for details on this condition
X連鎖重症複合免疫不全症 Severe Combined Immunodeficiency, X-Linked IL2RG Xq13.1 Click here for details on this condition
ハイドロレタラス症候群 Hydrolethalus Syndrome HYLS1 11q24.2 Click here for details on this condition
鎌状赤血球症 Sickle-Cell Disease HBB 11p15.4 Click here for details on this condition
封入体ミオパチーⅡ型(GNEミオパチー) Inclusion Body Myopathy, Type 2 GNE 9p13.3 Click here for details on this condition
シェーグレン・ラルソン症候群 Sjögren-Larsson Syndrome ALDH3A2 17p11.2 Click here for details on this condition
イソ吉草酸血症 Isovaleric Acidemia IVD 15q15.1 Click here for details on this condition
一次性ネフローゼ症候群 Steroid-Resistant Nephrotic Syndrome NPHS2 1q25.2 Click here for details on this condition
メチルマロン酸血症MUT0型 Methylmalonic Aciduria, Type Mut(0) MMACHC 1p34.1 Click here for details on this condition
ストゥーブ・ウィードメン症候群 Stuve-Wiedemann Syndrome LIFR 5p13.1 Click here for details on this condition
ホモシスチン尿症を伴うメチルマロン酸血症cblD型 Methylmalonic Aciduria and Homocystinuria, Type cblD MMADHC 2q23.2 Click here for details on this condition
バルデー・ビードル症候群(BBS12関連) Bardet Biedl Syndrome (BBS12-related) BBS12 4q27 Click here for details on this condition
ムコ多糖症Ⅱ型(ハンター症候群、X連鎖性) Mucopolysaccharidosis, Type II [Hunter Syndrome], X-Linked IDS Xq28 Click here for details on this condition
ベータサラセミア Beta Thalassemia HBB 11p15.4 Click here for details on this condition
ムコ多糖症III型(サンフィリッポ症候群) Mucopolysaccharidosis, Type IIIC [Sanfilippo C] HGSNAT 8p11.21-p11.1 Click here for details on this condition
ビオチニダーゼ欠損症 Biotinidase Deficiency BTD 3p25.1 Click here for details on this condition
マルチプルスルファターゼ欠損症 Multiple Sulfatase Deficiency SUMF1 3p26 Click here for details on this condition
カナバン病 Canavan Disease ASPA 17p13.2 Click here for details on this condition
原発性線毛機能不全(DNAH5関連) Primary Ciliary Dyskinesia (DNAH5-related) DNAH5 5p15.2 Click here for details on this condition
カーペンター症候群 Carpenter Syndrome RAB23 6p12.1-p11.2 Click here for details on this condition
原発性線毛機能不全(DNAI1関連) Primary Ciliary Dyskinesia (DNAI1-related) DNAI1 14q24.3 Click here for details on this condition
糖原病Ⅰ型(Ia) Glycogen Storage Disease, Type 1A(BBS12-related) G6PC 17q21 Click here for details on this condition
原発性高シュウ酸尿症3型 Primary Hyperoxaluria, Type 3 HOGA1 10q24.2 Click here for details on this condition
糖原病Ⅰ型(Ib) Glycogen Storage Disease, Type 1B SLC37A4 11q23.3 Click here for details on this condition
濃化異骨症 Pycnody sostosis CTSK 1q21.3 Click here for details on this condition
糖原病Ⅲ型 Glycogen Storage Disease, Type 3 AGL 1p21.2 Click here for details on this condition
ピルビン酸デヒドロゲナーゼ欠損症 Pyruvate Dehydrogenase Deficiency (PDHB-Related) PDHB 3p14.3 Click here for details on this condition
糖原病VII型 Glycogen Storage Disease, Type 7 BCS1L 2q35 Click here for details on this condition
エカルディ・グティエール症候群 Aicardi-Goutières Syndrome SAMHD1 20q11.23 Click here for details on this condition
グレイシル症候群 GRACILE Syndrome BCS1L 2q35 Click here for details on this condition
アルポート症候群 Alport Syndrome, X-Linked COL4A5 Xq22.3 Click here for details on this condition
長鎖3-ヒドロキシアシルCoAデヒドロゲナーゼ欠損症 Long Chain 3-Hydroxyacyl-CoA Dehydrogenase Deficiency HADHA 2p23 Click here for details on this condition
アルストレーム症候群 Alstrom Syndrome ALMS1 2p13.1 Click here for details on this condition
リジン尿性蛋白不耐症 Lysinuric Protein Intolerance SLC7A7 14q11.2 Click here for details on this condition
アンダーマン症候群 Andermann Syndrome SLC12A6 15q14 Click here for details on this condition
メープルシロップ尿症ⅠB型 Maple Syrup Urine Disease, Type 1B BCKDHB 6q14.1 Click here for details on this condition
アロマターゼ欠損症 Aromatase Deficiency CYP19A1 15q21.2 Click here for details on this condition
メチルマロン酸血症(MMAA関連) Methylmalonic Acidemia (MMAA-related) MMAA 4q31.21 Click here for details on this condition
重症先天性好中球減少症 (HAX1関連) Congenital Neutropenia (HAX1-related) HAX1 1q21.3 Click here for details on this condition
クリグラー・ナジャー症候群Ⅰ型 Crigler Najjar Syndrome, Type I UGT1A1 2q37.1 Click here for details on this condition
ツェルウェガー症候群(PEX2) Peroxisome Biogenesis Disorders Zellweger Syndrome Spectrum (PEX2-related) PEX2 8q21.13 Click here for details on this condition
嚢胞性線維症 Cystic Fibrosis CFTR 7q31.2 Click here for details on this condition
フェニルケトン尿症 Phenylketonurea PAH 12q23.2 Click here for details on this condition
第XI因子欠乏症 Factor XI Deficiency F11 4q35.2 Click here for details on this condition
橋小脳形成不全1A型 Pontocerebellar Hypoplasia, Type 1A VRK1 14q32.2 Click here for details on this condition
家族性自律神経失調症 Familial Dysautonomia IKBKAP 9q31.3 Click here for details on this condition
橋小脳形成不全2D型 Pontocerebellar Hypoplasia, Type 2D SEPSECS 4p15.2 Click here for details on this condition
ジュベール症候群関連疾患 Joubert Syndrome, Type 2 LAMC2 1q25.3 Click here for details on this condition
橋小脳形成不全2E型 Pontocerebellar Hypoplasia, Type 2E VPS53 17p13.3 Click here for details on this condition
接合部型表皮水疱症(ヘルリッツ型) Junctional Epidermolysis Bullosa, Herlitz Type LAMC2 1q25.3 Click here for details on this condition
テイサックス病 Tay-Sachs Disease HEXA 15q23 Click here for details on this condition
葉状魚鱗癬Ⅰ型 Lamellar Ichthyosis, Type 1 TGM1 14q12 Click here for details on this condition
アッシャー症候群タイプ1F Usher Syndrome, Type 1F PCDH15 10q21.1 Click here for details on this condition
レーベル先天性黒内障(LCA5関連) Leber Congenital Amaurosis (LCA5-related) LCA5 6q14.1 Click here for details on this condition
アッシャー症候群タイプ3 Usher Syndrome, Type 3 CLRN1 3q25.1 Click here for details on this condition
リー脳症(フランス-カナダ型) Leigh Syndrome, French-Canadian Type LRPPRC 2p21 Click here for details on this condition
ウォルマン病 Wolman Disease LIPA 10q23.31 Click here for details on this condition
X連鎖性ミオチュブラーミオパチー Myotubular Myopathy, X-Linked MTM1 Xq28 Click here for details on this condition
メチルグルタコン酸尿症 3-Methylglutaconic Aciduria, Type 3 [Costeff Syndrome], OPA3 Click here for details on this condition
ナバホ神経肝障害(MPV17関連の肝脳ミトコンドリアDNA枯渇症候群) Navajo Neurohepatopathy [MPV17-related Hepatocerebral Mitochondrial DNA Depletion Syndrome] MPV17 2p23.3 Click here for details on this condition
無βリポタンパク血症 Abetalipoproteinemia MTTP Click here for details on this condition
急性乳幼児肝不全(TRMU関連) Acute Infantile Liver Failure (TRMU-related) TEMU Click here for details on this condition
神経セロイドリポフスチン症(CLN8関連) Neuronal Ceroid Lipofuscinosis (CLN8-related) CLN8 8p23 Click here for details on this condition
アルギニノコハク酸リアーゼ欠乏症 Argininosuccinate Lyase Deficiency, ASL ASL Click here for details on this condition
神経セロイドリポフスチン症(MFSD8関連) Neuronal Ceroid Lipofuscinosis (MFSD8-related) MFSD8 4q28.2 Click here for details on this condition
毛細血管拡張性運動失調症 Ataxia-Telangiectasia, ATM ATM Click here for details on this condition
神経セロイドリポフスチン症(TPP1関連) Neuronal Ceroid Lipofuscinosis (TPP1-related) TPP1 11p15.4 Click here for details on this condition
シャルルボワ・サグネの常染色体潜性痙性運動失調症 Autosomal Recessive Spastic Ataxia of Charlevoix- Saguenay, SACS SACS Click here for details on this condition
ナイミーヘン染色体不安定症候群 Nijmegen Breakage Syndrome NBN 8q21.3 Click here for details on this condition
原発性免疫不全症候群 Bare Lymphocyte Syndrome (CIITA-related), CIITA CIITA Click here for details on this condition
網膜ジストロフィー Retinal Dystrophy (RLBP1-related) [Bothnia Retinal Dystrophy] RLBP1 15q26.1 Click here for details on this condition
ミトコンドリア “Combined Oxidative Phosphorylation Deficiency 1, GFM1” GFM1 Click here for details on this condition
フィンランド型先天性ネフローゼ症候群 Congenital Finnish Nephrosis, NPHS1 NPHS1 Click here for details on this condition
網膜色素変性症-25 Retinitis Pigmentosa 25 (EYS-related) EYS 6q12 Click here for details on this condition
先天性筋無力症候群 “Congenital Myasthenic Syndrome (RAPSN-related), RAPSN” RAPSN Click here for details on this condition
網膜色素変性症-59 Retinitis Pigmentosa 59 (DHDDS-related) DHDDS 1p36.11 Click here for details on this condition
角膜内皮性異栄養症 Corneal Dystrophy and Perceptive Deafness, SLC4A11 SLC4A11 Click here for details on this condition
サンフィリポ症候群 Sanfilippo Syndrome, Type D [Mucopolysaccharidosis IIID] GNS 12q14.3 Click here for details on this condition
脳クレアチン欠乏症候群 Creatine Transporter Defect [Cerebral Creatine Deficiency Syndrome 1] X-Linked, SLC6A8 SLC6A8 Click here for details on this condition
重症複合免疫不全症(アサバスカ型) Severe Combined Immunodeficiency, Type Athabaskan DCLRE1C 10p13 Click here for details on this condition
シスチノーシス(シスチン症) Cystinosis, CTNS CTNS Click here for details on this condition
SLC35A3変異による関節拘縮、精神遅滞、および発作 Arthrogryposis Mental Retardation Seizures SLC35A3 1p21.2 Click here for details on this condition
デュシェンヌ型筋ジストロフィー Duchenne Muscular Dystrophy, X-linked, DMD l DMD Click here for details on this condition
SLC35A3変異による関節拘縮、精神遅滞、および発作 Arthrogryposis Mental Retardation Seizures SLC35A3 1p21.2 Click here for details on this condition
Emery-Dreifuss 型筋ジストロフィー Emery-Dreifuss Muscular Dystrophy 1, X-Linked, EMD EMD Click here for details on this condition
アスパラギン合成酵素欠損症 Asparagine Synthetase Deficiency ASNS 7q21.3 Click here for details on this condition
ファブリー病、X連鎖性 Fabry Disease, X-Linked, GLA GLA Click here for details on this condition
アスパルチルグルコサミン尿症 Aspartylglycosaminuria AGA 4q34.3 Click here for details on this condition
家族性地中海熱 Familial Mediterranean Fever, MEFV MEFV Click here for details on this condition
常染色体潜性多発性嚢胞腎 Autosomal Recessive Polycystic Kidney Disease PKHD1 6p12.3-p12.2 Click here for details on this condition
ガラクトース-1-リン酸ウリジルトランスフェラーゼ欠損症 Galactosemia, GALT u GALT Click here for details on this condition
バルデー・ビードル症候群(BBS1関連) Bardet-Biedl Syndrome (BBS1-related) BBS1 11q13.2 Click here for details on this condition
遺伝性ヘモクロマトーシス Hemochromatosis, Type 3 (TFR2-related), TFR2 TFR2 Click here for details on this condition
ファンコニ貧血C型 Fanconi Anemia, Type C FANCC 9q22.32 Click here for details on this condition
眼皮膚白皮症 Hermansky-Pudlak Syndrome (HPS3-related), HPS3 HPS3 Click here for details on this condition
ファンコニ貧血G型 Fanconi Anemia, Type G FANCG 9p13.3 Click here for details on this condition
低ホスファターゼ症 Hypophosphatasia (ALPL-related), ALPL ALPL Click here for details on this condition
ホスホグリセリン酸脱水素酵素欠損症 “3-Phosphoglycerate Dehydrogenase Deficiency, PHGDH” PHGDH Click here for details on this condition
ゴーシェ病 Gaucher Disease GBA 1q21 Click here for details on this condition
グルタル酸血症ⅡA型 Glutaric Acidemia, Type 2A ETFA 15q24.2-q24.3 Click here for details on this condition
非ケトーシス型高グリシン血症(グリシン脳症) Glycine Encephalopathy (GLDC-related) GLDC 9p24.1 Click here for details on this condition
白質消失病 Leukoencephalopathy with Vanishing White Matter EIF2B5 3q27.1 Click here for details on this condition
Disease Name (JP) Disease Name (EN) Genes Tested at Our Clinic Detailed Information
自己免疫性多内分泌腺症候群 1型 Autoimmune Polyglandular Syndrome, Type 1, AIRE AIRE Click here for details on this condition
ツェルウェガー症候群(PEX1) Peroxisome Biogenesis Disorders Zellweger Syndrome Spectrum (PEX1-related), PEX1 PEX1 Click here for details on this condition
膠様滴状角膜ジストロフィー Bartter Syndrome (BSND-related), BSND BSND Click here for details on this condition
関連複合下垂体ホルモン欠損症 Pituitary Hormone Deficiency, Combined 3, LHX3 LHX3 Click here for details on this condition
ヒルシュスプルング病 Cartilage-Hair Hypoplasia, RMRP RMRP Click here for details on this condition
原発性毛様体ジスキネジア、DNAI1関連、DNAI1 Primary Ciliary Dyskinesia, DNAI1-related, DNAI1 DNAI1 Click here for details on this condition
ヒトアルギニノスクシネートシンテターゼ Citrullinemia, Type 1, ASS1 ASS1 Click here for details on this condition
原発性高シュウ酸尿症 Primary Hyperoxaluria, Type 2, GRHPR GRHPR Click here for details on this condition
先天性グリコシル化異常症 Congenital Disorder of Glycosylation, Type 1B, MPI MPI Click here for details on this condition
ピルビン酸デヒドロゲナーゼ複合体欠損症 “Pyruvate Dehydrogenase Deficiency (PDHB-related), PDHB” PDHB Click here for details on this condition
先天性無痛症 “Congenital Insensitivity to Pain with Anhidrosis, NTRK1” NTRK1 Click here for details on this condition
RLBP1関連網膜ジストロフィー (ボスニア網膜ジストロフィー) Retinal Dystrophy (RLBP1-related) [Bothnia Retinal Dystrophy], RLBP RLBP Click here for details on this condition
アルドステロン合成酵素欠損症 Corticosterone Methyloxidase Deficiency, CYP11B2 CYP11B2 Click here for details on this condition
網膜色素変性症 26 Retinitis Pigmentosa 26, CERKL CERKL Click here for details on this condition
D-二頭酵素(DBP)欠損症 D-Bifunctional Protein Deficiency, HSD17B4 HSD17B4 Click here for details on this condition
1型穿孔性軟骨異形成症(Rhizomelic Chondrodysplasia Punctata) Rhizomelic Chondrodysplasia Punctata, Type 1, PEX7 PEX7 Click here for details on this condition
表皮水疱症 “Dystrophic Epidermolysis Bullosa (COL7A1-related), COL7A1” COL7A1 Click here for details on this condition
サラー病 Salla Disease, SLC17A5 SLC17A5 Click here for details on this condition
瀬川症候群、(TH関連) Segawa Syndrome, (TH-related), TH TH Click here for details on this condition
変異関連網膜変性症 Enhanced S-Cone Syndrome, NR2E3 NR2E3 Click here for details on this condition
鎌状赤血球症 Sickle-Cell Disease, HBB l HBB l Click here for details on this condition
第IX因子欠乏症、X連鎖性 Factor IX Deficiency, X-Linked, F9 F9 Click here for details on this condition
テイサックス病、HEXA u Tay-Sachs Disease, HEXA u HEXA Gene Click here for details on this condition
先天性腎性尿崩症 Familial Nephrogenic Diabetes Insipidus (AQP2- related), AQP2 AQP2 Click here for details on this condition
ウィルソン病 Wilson Disease, ATP7B ATP7B Click here for details on this condition
筋型糖原病 Glycogen Storage Disease, Type 4, GBE1 GBE1 Click here for details on this condition
ヘルリッツ型接合型表皮水疱症 Junctional Epidermolysis Bullosa, Herlitz type, LAMC2 LAMC2 Click here for details on this condition
PTPS欠損症 6-Pyruvoyl-Tetrahydropterin Synthase (PTPS) Deficiency, PTS PTS Click here for details on this condition
1型ラメラ魚鱗癬 Lamellar Ichthyosis, Type 1, TGM1 TGM1 Click here for details on this condition
アクロマトプシア(CNGB3関連) Achromatopsia (CNGB3-related), CNGB3 CNGB3 Click here for details on this condition
リー症候群、フランス系カナダ人型 Leigh Syndrome, French-Canadian Type, LRPPRC LRPPRC Click here for details on this condition
副腎白質ジストロフィー Adrenoleukodystrophy, X-Linked, ABCD1 ABCD1 Click here for details on this condition
2A型 四肢帯状筋ジストロフィー Limb-Girdle Muscular Dystrophy, Type 2A, CAPN3 CAPN3 Click here for details on this condition
アルポート症候群 Alport Syndrome (COL4A3-related), COL4A3 COL4A3 Click here for details on this condition
肢帯型筋ジストロフィー、2型 Limb-Girdle Muscular Dystrophy, Type 2D, SGCA SGCA Click here for details on this condition
ビタミンE欠乏症に伴う運動失調症 Ataxia with Vitamin E Deficiency, TTPA TTPA Click here for details on this condition
リポイド副腎過形成症 Lipoid Adrenal Hyperplasia, STAR STAR Click here for details on this condition
バッテン病(CLN3関連) Batten Disease (CLN3-related), CLN3 CLN3 Click here for details on this condition
中鎖アシル-CoAデヒドロゲナーゼ欠乏症 “Medium Chain Acyl-CoA Dehydrogenase Deficiency, ACADM u” ACADM u Click here for details on this condition
ブルーム(Bloom)症候群 Bloom Syndrome, BLM u BLM Click here for details on this condition
メタクロマチック・ロイコジストロフィー(PSAP関連) Metachromatic Leukodystrophy (PSAP-related) PSAP PSAP Click here for details on this condition
カルニチンパルミトイル基転移酵II欠損症 Carnitine Palmitoyltransferase II Deficiency, CPT2 CPT2 Click here for details on this condition
メチルマロン酸尿症・ホモシスチン尿症 cblC型 Methylmalonic Aciduria and Homocystinuria, Type cblC, MMACHC MMACHC Click here for details on this condition
脳腱黄色腫症 Cerebrotendinous Xanthomatosis, CYP27A1 CYP27A1 Click here for details on this condition
小眼球症/無眼球症(VSX2関連) Microphthalmia/Anophthalmia (VSX2-related), VSX2 VSX2 Click here for details on this condition
慢性肉芽腫症 Chronic Granulomatous Disease, X-Linked, CYBB CYBB Click here for details on this condition
ミトコンドリア複合体1欠損症(NDUFS6関連), Mitochondrial Complex 1 Deficiency (NDUFS6-related), NDUFS6 NDUFS6 Click here for details on this condition
マロン酸尿症とメチルマロン酸尿症 Combined Malonic and Methylmalonic Aciduria, ACSF3 Click here for details on this condition
ライソゾーム病(ムコリピドーシス III型) Mucolipidosis III Gamma, GNPTG GNPTG Click here for details on this condition
ムコ多糖症IIIB型[Sanfilippo B]、 “Mucopolysaccharidosis, Type IIIB [Sanfilippo B], NAGLU” NAGLU Click here for details on this condition
PROP1関連複合下垂体ホルモン欠損症 Combined Pituitary Hormone Deficiency 2, PROP1 PROP1 Click here for details on this condition
ライソゾーム病(ムコ多糖症IX型、ヒアルロニダーゼ欠損症) Mucopolysaccharidosis, Type IX, HYAL1 HYAL1 Click here for details on this condition
先天性N-結合グリコシル化経路異常症 Congenital Disorder of Glycosylation Type 1C, ALG6 ALG6 Click here for details on this condition
先天性筋無力症候群 “Congenital Myasthenic Syndrome (CHRNE-related), CHRNE” CHRNE Click here for details on this condition
神経セロイドリポフスチン症 Neuronal Ceroid Lipofuscinosis (CLN6-related), CLN6 CLN6 Click here for details on this condition
先天性筋無力症候群 “Congenital Myasthenic Syndrome (CHRNE-related), CHRNE” CHRNE Click here for details on this condition
酸性スフィンゴミエリナーゼ欠損症 Niemann-Pick Disease, Types A/B, SMPD1 u SMPD1 Click here for details on this condition
先天性好中球減少症 Congenital Neutropenia (VPS45-related), VPS45 VPS45 Click here for details on this condition
ミトコンドリア病 Pontocerebellar Hypoplasia, RARS2-related, RARS2 RARS2 Click here for details on this condition
CRB1関連の網膜ジストロフィー CRB1-related Retinal Dystrophies, CRB1 CRB1 Click here for details on this condition
線毛機能不全症候群 Primary Ciliary Dyskinesia, DNAI2-related, DNAI2 DNAI2 Click here for details on this condition
難聴、常染色体潜性77 Deafness, Autosomal Recessive 77, LOXHD1 LOXHD1 Click here for details on this condition
ピルビン酸脱水素酵素複合体欠損症 Pyruvate Dehydrogenase Deficiency, X-Linked, PDHA1 PDHA1 Click here for details on this condition
エーラス・ダンロス症候群 Ehlers-Danlos Syndrome, Type VIIC, ADAMTS ADAMTS Click here for details on this condition
網膜色素変性症 Retinitis Pigmentosa 28, FAM161A FAM161A Click here for details on this condition
エチルマロン酸脳症 Ethylmalonic Encephalopathy, ETHE1 ETHE1 Click here for details on this condition
肢根型点状軟骨異形成症III型 (RCDP3) Rhizomelic Chondrodysplasia Punctata, Type 3, AGPS AGPS Click here for details on this condition
第V因子欠乏症 Factor V Leiden Thrombophilia, F5 F5 Click here for details on this condition
サンドホフ病 Sandhoff Disease, HEXB HEXB Click here for details on this condition
家族性高コレステロール血症 Familial Hypercholesterolemia (LDLR-related), LDLR LDLR Click here for details on this condition
高チロシン血症1型 Tyrosinemia, Type 1, FAH FAH Click here for details on this condition
ガラクトキナーゼ欠損症 “Galactokinase Deficiency [Galactosemia, Type II], GALK1” GALK1 Click here for details on this condition
アッシャー症候群 Usher Syndrome, Type 2A, USH2A USH2A Click here for details on this condition
グルタル酸血症1型 Glutaric Acidemia, Type 1, GCDH GCDH Click here for details on this condition
網膜分離症 Juvenile Retinoschisis, X-Linked, RS1 RS1 Click here for details on this condition
非ケトーシス型高グリシン血症 Glycine Encephalopathy (AMT-related), AMT AMT Click here for details on this condition
筋ジストロフィー Limb-Girdle Muscular Dystrophy, Type 2B, DYSF DYSF Click here for details on this condition
糖原病II型(ポンぺ病) “Glycogen Storage Disease, Type 2 [Pompe Disease], GAA” GAA Click here for details on this condition
皮質下嚢胞を伴う巨頭性白質脳症 Megalencephalic Leukoencephalopathy with Subcortical Cysts, MLC1 MLC1 Click here for details on this condition
糖原病V型 “Glycogen Storage Disease, Type 5 [McArdle Disease], PYGM” PYGM Click here for details on this condition
ミトコンドリア複合体1欠損症(ACAD9関連) Mitochondrial Complex 1 Deficiency (ACAD9-related), ACAD9 ACAD9 Click here for details on this condition
若年性ヘモクロマトーシス Hemochromatosis, Type 2A, HFE2 HFE2 Click here for details on this condition
ミトコンドリア性ミオパチーと鉄芽球性貧血(MLASA1)、PUS1 Mitochondrial Myopathy and Sideroblastic Anemia (MLASA1), PUS1 PUS1 Click here for details on this condition
ヘルマンスキー・パドラック症候群1 Hermansky-Pudlak Syndrome (HPS1-related), HPS1 HPS1 Click here for details on this condition
ムコリピドーシス(IV型) Mucolipidosis, Type IV, MCOLN1 u MCOLN1 u Click here for details on this condition
ホモシスチン尿症 Homocystinuria (CBS-related), CBS CBS Click here for details on this condition
N-アセチルグルタミン酸シンターゼ欠乏症 N-acetylglutamate Synthase Deficiency, NAGS NAGS Click here for details on this condition
無汗性外胚葉形成不全症 Hypohidrotic Ectodermal Dysplasia, X-Linked, EDA EDA Click here for details on this condition
ニーマン・ピック病 C1/D型 Niemann-Pick Disease, Type C1/D, NPC1 NPC1 Click here for details on this condition
クラッベ病 Krabbe Disease, GALC GALC Click here for details on this condition
非シンドローム性難聴(GJB2関連、GJB6関連) Non-Syndromic Hearing Loss (GJB2-related, GJB6-related), GJB2, GJB6 GJB2, GJB6 Click here for details on this condition
レーベル遺伝性視神経症 Leber Congenital Amaurosis, Type CEP290, CEP290 CEP290 Click here for details on this condition
オルニチンアミノトランスフェラーゼ欠乏症 Ornithine Aminotransferase Deficiency, OAT OAT Click here for details on this condition
肢帯型筋ジストロフィー Limb-Girdle Muscular Dystrophy, Type 2C, SGCG SGCG Click here for details on this condition
フェニルケトン尿症 Phenylketonurea, PAH u PAH u Click here for details on this condition
ジヒドロリポアミドデヒドロゲナーゼ欠損症 Lipoamide Dehydrogenase Deficiency [Maple Syrup Urine Disease, Type 3], DLD DLD Click here for details on this condition
原発性高シュウ酸尿症Ⅰ型 Primary Hyperoxaluria, Type 1, AGXT AGXT Click here for details on this condition
長鎖3-ヒドロキシアシルCoA脱水素酵素欠損症 Long Chain 3-Hydroxyacyl-CoA Dehydrogenase Deficiency, HADHA HADHA Click here for details on this condition
腎尿細管性アシドーシスと難聴(ATP6V1B1-関連)、ATP6V1B Renal Tubular Acidosis and Deafness (ATP6V1B1- related), ATP6V1B ATP6V1B Click here for details on this condition
ジュベール症候群関連疾患 Meckel-Gruber Syndrome, Type 1, MKS1 MKS1 Click here for details on this condition
X連鎖性網膜色素変性症 Retinitis Pigmentosa, X-linked, RPGR RPGR Click here for details on this condition
異染性白質ジストロフィー Metachromatic Leukodystrophy (ARSA-related), ARSA ARSA Click here for details on this condition
ロバーツ症候群 Roberts Syndrome, ESCO2 ESCO2 Click here for details on this condition
メチルマロン酸血症 Methylmalonic Aciduria (MMAB-related), MMAB MMAB Click here for details on this condition
シムケ免疫性骨形成不全 Schimke Immunoosseous Dysplasia, SMARCAL1 SMARCAL1 Click here for details on this condition
メチルマロン酸血症MUT0型 Methylmalonic Aciduria, Type mut(0), MMUT MMUT Click here for details on this condition
スミス・レムリ・オピッツ症候群、DHCR7 u Smith-Lemli-Opitz Syndrome, DHCR7 u DHCR7 u Click here for details on this condition
ミトコンドリア複合体 I 欠損症 Mitochondrial Complex 1 Deficiency (NDUFAF5- related), NDUFAF5 NDUFAF5 Click here for details on this condition
Stuve-Wiedemann症候群 Stuve-Wiedemann Syndrome, LIFR HSPG2 Click here for details on this condition
ムコリピドーシスⅢ型 Mucolipidosis II/III, GNPTAB GNPTAB Click here for details on this condition
アッシャー症候群(1C型)USH1C Usher Syndrome, Type 1C, USH1C USH1C Click here for details on this condition
ミトコンドリア神経胃腸脳症疾患 “Myoneurogastrointestinal Encephalopathy (MNGIE), TYMP” TYMP Click here for details on this condition
ゼルウィガー・スペクトラム障害、(PEX6関連)、PEX6 Zellweger Spectrum Disorders, (PEX6-related), PEX6 PEX6 Click here for details on this condition
ナバホ神経肝症[MPV17関連肝細胞ミトコンドリアDNA欠失症候群] Navajo Neurohepatopathy [MPV17-related Hepatocerebral Mitochondrial DNA Depletion Syndrome], MPV17 MPV17 Click here for details on this condition
ゼルウィガー・スペクトラム障害(PEX10関連)、PEX10 Zellweger Spectrum Disorders (PEX10-related), PEX10 PEX10 Click here for details on this condition
CLN5 疾患 Neuronal Ceroid Lipofuscinosis (CLN5-related), CLN5 CLN5 Click here for details on this condition
神経セロイドリポフスチン症 Neuronal Ceroid Lipofuscinosis (PPT1-related), PPT1 PPT1 Click here for details on this condition
ニーマン・ピック病、C2型、NPC2型 Niemann-Pick Disease, Type C2, NPC2 NPC2 Click here for details on this condition
オドント・オニーコ・皮膚異形成症・”オドント・オニーコ・皮膚異形成症、ショプフ・シュルツ・パサージ症候群 “Odonto-Onycho-Dermal Dysplasia / Schopf-Schulz- Passarge Syndrome, WNT10A” WNT10A Click here for details on this condition
オルニチントランスカルバミラーゼ欠損症 Ornithine Transcarbamylase Deficiency, OTC OTC Click here for details on this condition

Understanding Recessive Genetic Disorders at Hiro Clinic

At Hiro Clinic, we offer prenatal testing to screen genes associated with severe recessive genetic disorders. This test extracts and analyzes genetic material from mucosal cells collected from the inner cheek of both the mother and father. Based on their combined genetic information, it determines whether the fetus is at risk of inheriting a severe genetic condition. In our clinic’s findings to date, approximately 70% of individuals carry at least one recessive gene mutation. Even if you are a carrier, you will almost never experience any symptoms yourself.

For instance, even with a rare recessive genetic disorder that affects only 1 in 40,000 individuals, 1 in 100 people is a carrier (someone who holds a gene mutation without developing symptoms). This test is valuable for identifying whether both the mother and father are carriers and predicting the risk of recessive genetic conditions.

At Hiro Clinic, we believe that identifying carrier genes and evaluating potential links to recessive genetic disorders based on parental gene combinations makes this a highly useful screening test.

A key feature of this test is that it detects all gene combinations previously associated with genetic anomalies to determine whether a specific genetic variant is genuinely pathogenic.

Genes vary from individual to individual. This variability is common even among critical genes, and this natural diversity is what makes each person unique. However, certain genetic variants can carry pathogenic risks.

Information on gene combinations is shared in global databases. By searching these databases, we can assess whether a specific genetic change carries pathogenic significance.

When both the mother and father carry pathogenic variants at the exact same location, there is a high risk of the child developing the condition. However, simply looking at genetic variants alone is not enough; it is essential to accurately analyze and classify (annotate) whether a genetic change is truly a disease-causing abnormality.

Below is a summary recommendation issued in the United States by the American College of Obstetricians and Gynecologists (ACOG). It emphasizes that, at a minimum, all pregnant women should be provided with information about the availability of such testing.

ACOG Committee Opinion (No. 691) Summary / Excerpt

・All pregnant women should be provided with information about genetic carrier screening. Patients also have the option to decline testing after receiving counseling.
・Carrier screening and counseling are ideally performed prior to pregnancy (preconception).
・If an individual is identified as a carrier, their partner should also be offered testing following counseling. When time is limited for making prenatal diagnostic decisions, simultaneous testing for both the patient and partner is recommended.
・If both partners are identified as carriers, counseling should be provided. Prenatal diagnosis or assisted reproductive technologies should be considered to reduce the risk of having an affected child.
・If an individual is found to be a carrier, their relatives are also at risk for the same mutation. Therefore, the patient should be encouraged to inform them of this risk and the availability of carrier screening. Obstetricians, gynecologists, and healthcare providers must not disclose this information without the patient’s permission.
・It is important to obtain the patient’s family history and, if possible, the partner’s genetic background and risks. The family history should include the family’s ethnic background and any consanguinity (blood relation). If a family history is present, screening for specific conditions should be offered, and the patient may benefit from counseling.
・Screening for specific conditions should be performed only once in a person’s lifetime, and the results should be saved in the patient’s medical records. However, because advances in genetic testing are rapid, new screening panels may include additional mutations. Decisions regarding re-testing should be made under the guidance of a genetics professional, who can best evaluate the benefits of re-testing to identify new mutations.
・Prenatal carrier screening does not replace newborn screening, nor does newborn screening replace the potential value of prenatal carrier screening.
・If a patient requests carrier screening for specific conditions that are available and reasonable compared to other screening options, the requested screening should be offered to the patient (regardless of ethnicity or family history) after they have been informed of the risks, benefits, and limitations of the test.
・The cost of individual condition-based carrier screening can sometimes be higher than commercially available expanded carrier screening (ECS). When selecting a carrier screening approach, the costs to both the patient and the healthcare system should be taken into consideration.

About Testing for Recessive Genetic Disorder Genes

Testing Method / Limitations of Testing

Genomic deoxyribonucleic acid (gDNA) is extracted using a standardized method and mechanically fragmented prior to DNA library preparation.
Target genomic regions are enriched using solution-based hybridization methods, and sequencing is performed via Next-Generation Sequencing (NGS).
The generated sequence reads are aligned to a reference genome, and variants are identified using a proprietary bioinformatics pipeline.
For recessive inheritance, single nucleotide variants (SNVs), small insertions and deletions (indels ≤ 30 bp), and copy number variations (CNVs) can be detected.
Variants are classified according to the criteria of the American College of Medical Genetics and Genomics (ACMG) tiers 3–5.
Variant classification and interpretation are performed using the Varsome Clinical platform, based on the information available at the time of testing.
Only pathogenic and likely pathogenic variants are reported. Variants detected that are classified as variants of uncertain significance (VUS), benign, or likely benign will not be reported.
Genetic counseling is recommended regarding clinical interpretation and results.

A: For Autosomal Results:
A-1: “No clinically significant variants detected”
While this does not completely guarantee that the subject is not a carrier of a hereditary condition, it indicates the absence of identified gene mutations, suggesting a low likelihood of being a carrier.
A-2: “Clinically significant variant(s) detected”
Indicates that a genetic change was identified, showing that the subject is a carrier for that condition. In such cases, the subject may be a carrier for two or more conditions.
Carriers usually do not exhibit symptoms of the disease. However, if both copies of the chromosome show mutations, the possibility that the subject is currently affected or may develop symptoms in the future cannot be ruled out.

B: For X-Linked Inherited Conditions:
B-1: “No clinically significant variants detected”
Indicates that no hereditary variants were found. If the subject is male, this suggests he is unaffected; if female, it indicates a low likelihood of being a carrier, though it cannot be completely ruled out.
B-2: “Clinically significant variant(s) detected”:
Indicates that a genetic alteration was identified. Female subjects may be carriers.
If the subject is male, this indicates that he is currently affected or has the potential to develop the disease in the future. However, because conditions in this panel vary in severity, clinical symptoms may not manifest.
The purpose of the assay is to detect all variants associated with the covered genes by targeting all coding exons, MANE and/or canonical transcripts, and 10 bp of flanking intronic sequences.
Variants outside the target regions are not intended to be detected by this assay.
Unless explicitly stated otherwise, sequence changes (SNVs and indels) in promoter regions and other non-coding regions are not detected by this assay.
Specific sequence changes (SNVs and indels) in non-coding regions deemed clinically significant for the detected genes are included in the analysis.
If two variants are identified in a single gene, this test cannot distinguish whether they reside on the same chromosome (cis) or on opposite chromosomes (trans).
Genetic alterations such as inversions, rearrangements, polyploidy, and epigenetic modifications are not targeted by this test.
Specific sequence alterations (SNVs and indels) in target regions with repetitive sequences, highly homologous sequences such as segmental duplications and pseudogenes, as well as high/low GC-content regions may not be detected.
Copy Number Variations (CNVs) are calculated using uniquely mapped, high-quality sequencing reads while avoiding duplicates.
Using GC-content normalization and depth-of-sequencing coverage approaches, CNVs are detected for a subset of the target regions.
A CNV abnormality is identified when the observed coverage deviates significantly from the expected coverage derived from baseline references.
CNV detection is capable down to a resolution of a few exons.
If a positive CNV is detected, it is confirmed using orthogonal methods.
CNVs cannot be reliably detected in genomic regions containing poorly mapped areas, repetitive sequences, pseudogenes, or extreme GC content.

Because CNV detection using NGS has lower sensitivity and specificity compared to orthogonal quantitative methods, the absence of a reported CNV does not guarantee that no CNVs exist.
The absence of disease-causing variants in the targeted genes reduces the likelihood of disease but does not completely eliminate the possibility of disease-related syndromes.

Additional Information & Disclosures

The test may not identify all variants associated with the analyzed conditions.
Although this test is highly accurate, the possibility of false-positive or false-negative results still exists and may be caused by technical or biological limitations.
These include rare genetic variants, mosaicism, blood transfusions, bone marrow transplants, or other rare molecular events.
Some unexamined genetic alterations may lead to disease conditions and are not tested by this carrier screening test.
Although genetic testing is a crucial part of the diagnostic process, it does not always yield definitive answers. In some cases, a genetic variant may be present even if the test fails to identify it.
This stems from current limitations in medical knowledge or laboratory technology.
It is recommended to use this test concurrently with other clinical data and findings.
Results should always be considered in the context of broader clinical findings.
The referring clinician is responsible for pre- and post-test counseling, including advising on the necessity of any additional genetic testing.
Other diagnostic procedures or tests may be necessary in some instances.

Supervised By

Hiroshi Oka, M.D., Ph.D. / Executive Medical Director & Lab Director, Hiro Clinic (Fukubukai Medical Corporation)
After graduating from Keio University School of Medicine, Dr. Oka passed the medical licensing examinations in both Japan and the United States. Following clinical residency, he earned his Doctorate in Medicine (Ph.D.). Holding a certified Lab Director credential—a distinction held by only about 20 individuals in Japan—he is dedicated to prenatal testing and genetic counseling in close collaboration with specialists in obstetrics, gynecology, pediatrics, and clinical genetics.

Frequently Asked Questions

Q. What is a “carrier”?

A carrier is a person who has a genetic mutation but exhibits no symptoms. As long as one copy of the gene is normal, the disorder will not develop. In Japan, approximately 70% of people are estimated to be carriers of at least one condition.

Q. Why do both partners need to undergo testing together?

Recessive genetic disorders present a risk to the child when both the mother and father carry a mutation in the same gene. Because results from only one parent are insufficient to evaluate risk, undergoing couple/pair testing together is crucial.

Q. When will I receive my results?

Results will be reported via email approximately 3 weeks after the collected sample arrives at the laboratory. This report is delivered separately from NIPT (blood draw) results.

Q. What should we do if a high risk is identified?

Amniocentesis may be recommended as a diagnostic confirmatory test. By enrolling in our Amniocentesis Support program, you can receive up to ¥300,000 (tax included) in subsidies depending on your plan.

Q. Can I take this test alongside NIPT?

Yes, they can be combined. For patients undergoing NIPT, Carrier Screening Test 231 is offered at a discounted optional price. Those who are not undergoing NIPT can also take this test as a standalone option.

Q. Is the test painful?

No. The sample is collected simply by gently swabbing the inside of the cheek (buccal mucosa) with a dedicated kit. Since no blood sampling or needles are used, the test is completely painless.

医師監修 監修日:2024年1月10日
岡 博史 (医師・医学博士/ヒロクリニック統括院長)

日本皮膚科学会 皮膚科専門医/日本医師会 産業医/東京衛生検査所 指導監督医

この記事は、 ヒロクリニックNIPTの編集・監修体制 にもとづき、資格を持つ医師が内容を確認しています。